Please provide your email address to receive an email when new articles are posted on . Risk for major adverse CV events was similar for adults receiving tirzepatide vs. dulaglutide. All-cause ...
PHILADELPHIA, PA—Mirroring results in patients with type 2 diabetes, semaglutide (Wegovy; Novo Nordisk) reduces cardiovascular events in patients with overweight or obesity and preexisting CVD who are ...
Please provide your email address to receive an email when new articles are posted on . This installment of Pipeline Pulse focuses on a single cardiovascular risk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results